T1DM
Intensive glycemic control
DCCT
Strict glycemic control prevents upto 70% of microvascular complications particularly retinopathy
EDIC
long term follow up to the DCCT - intensive glycemic control reduced the subsequent risk of CV events as well
42% and severe CV events by 57% at 11 yrs among pts with T1DM
Metabolic memory
T1GER
Among children and young adults with newly diagnosed overt type 1 diabetes, golimumab resulted in better endogenous insulin production and less exogenous insulin use than placebo.
DEPICT-1
In patients with type 1 diabetes, the addition of Dapagliflozin leads to a decrease in HbA1c over a 52-week period, promotes weight loss, and allows for a decrease in the dose of insulin administered, however,
an increase in incidence of DKA
T2DM
Intensive glycemic control
UKPDS 33
Intensive glycemic control (FBS<108) that reduces Hba1c by 11% over 10 years associated with a 25% reduction microvascular complications ,
NO effect on macrovascular disease or mortality among pts with T2DM
ADVANCE
Intensive glycemic control targeting HbA1c ≤6.5% improves microvascular outcomes but has